This paper summarizes the industry guidelines related to cell and gene therapy issued by the Food and Drug Administration (FDA).

Stem cell technology is expected to revolutionize the healthcare industry in an unprecedented way, especially in the fight against chronic diseases, in the next five to 10 years.

How to balance the "potential" and "tumorigenic risk" in stem cell therapy is one of the core challenges in this field.

iPSC can be treated with an ideal combination of growth factors and culture conditions to differentiate into specified cell types.

Scientists have found that a class of omnipotent stem cells, through proliferation, differentiation, renewal and replication to produce new, healthy organs and tissues, thus extending the life span of human beings.

At present, the main methods of cell therapy are divided into two categories: immune cell therapy and stem cell therapy.

By the end of April (the first quarter of 2024), seven new drugs IND for mesenchymal stem cells (excluding hematopoietic stem cells) have been added in China, which have been approved by the Drug Evaluation Center (NMPA) of the State Drug Administration.

Recently, IQVIA, a global company in the field of life sciences, released a research report on the current status and future trends of cell and gene therapy.